Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$1.86 USD

1.86
784,833

+0.03 (1.36%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.86 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat

by Zacks Equity Research

BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 28.30% and 8.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -200% and 93.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 1,400% and 273.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stevanato Group (STVN) Meets Q4 Earnings Estimates

by Zacks Equity Research

Stevanato (STVN) delivered earnings and revenue surprises of 0% and 1.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 14.94% and 0.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

New Strong Buy Stocks for January 9th

by Zacks Equity Research

AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.

Zacks Equity Research

Durect (DRRX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BellRing Brands (BRBR) and Durect (DRRX) have performed compared to their sector so far this year.

Zacks Equity Research

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 6.82% and 21.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 29.41% and 12.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of -400% and 90.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging DURECT (DRRX) This Year?

by Zacks Equity Research

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

Zacks Equity Research

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Matches Q4 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 0% and 0.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -2.22% and 27.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?